Amy Beth Vanduyn Sells 639 Shares of Phreesia (NYSE:PHR) Stock

Key Points

• Amy Beth Vanduyn, SVP of Phreesia, Inc., sold 639 shares of the company at an average price of $22.36, totaling $14,288.04, resulting in a 0.57% decrease in her position.
• Phreesia's recent stock performance indicates a market capitalization of $1.38 billion and a current share price of $23.11, with a 52-week trading range of $17.07 to $32.76.
• Wall Street analysts have a consensus rating of "Moderate Buy" for Phreesia, with an average price target of $33.85 following recent reporting of improved quarterly revenue.

Phreesia, Inc. (NYSE:PHR - Get Free Report) SVP Amy Beth Vanduyn sold 639 shares of the stock in a transaction that occurred on Friday, October 17th. The shares were sold at an average price of $22.36, for a total value of $14,288.04. Following the transaction, the senior vice president directly owned 111,840 shares of the company's stock, valued at $2,500,742.40. The trade was a 0.57% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Amy Beth Vanduyn also recently made the following trade(s):

• On Tuesday, September 16th, Amy Beth Vanduyn sold 1,762 shares of Phreesia stock. The shares were sold at an average price of $23.28, for a total value of $41,019.36.

Phreesia Price Performance

Shares of Phreesia stock traded up $0.17 during mid-day trading on Tuesday, reaching $23.11. 370,773 shares of the stock traded hands, compared to its average volume of 611,887. The business has a 50-day moving average of $26.02 and a 200 day moving average of $25.99. Phreesia, Inc. has a fifty-two week low of $17.07 and a fifty-two week high of $32.76. The stock has a market capitalization of $1.38 billion, a PE ratio of -55.02 and a beta of 0.68. The company has a quick ratio of 2.12, a current ratio of 2.12 and a debt-to-equity ratio of 0.02.

Phreesia (NYSE:PHR - Get Free Report) last announced its earnings results on Thursday, September 4th. The company reported $0.01 EPS for the quarter, beating analysts' consensus estimates of ($0.07) by $0.08. Phreesia had a negative return on equity of 8.75% and a negative net margin of 5.35%.The business had revenue of $117.26 million during the quarter, compared to analysts' expectations of $116.39 million. During the same quarter in the prior year, the firm earned ($0.03) earnings per share. The business's revenue was up 14.9% compared to the same quarter last year. Phreesia has set its FY 2026 guidance at EPS. On average, analysts predict that Phreesia, Inc. will post -1.1 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. KBC Group NV purchased a new position in Phreesia in the first quarter worth approximately $74,000. Farther Finance Advisors LLC grew its position in Phreesia by 9,375.0% in the second quarter. Farther Finance Advisors LLC now owns 3,032 shares of the company's stock worth $86,000 after acquiring an additional 3,000 shares during the period. CWM LLC boosted its position in shares of Phreesia by 994.9% during the first quarter. CWM LLC now owns 4,040 shares of the company's stock worth $103,000 after buying an additional 3,671 shares during the period. Smartleaf Asset Management LLC boosted its position in shares of Phreesia by 53.0% during the first quarter. Smartleaf Asset Management LLC now owns 5,267 shares of the company's stock worth $137,000 after buying an additional 1,825 shares during the period. Finally, GAMMA Investing LLC boosted its position in shares of Phreesia by 10,605.7% during the first quarter. GAMMA Investing LLC now owns 5,674 shares of the company's stock worth $145,000 after buying an additional 5,621 shares during the period. 92.10% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on PHR shares. Weiss Ratings restated a "sell (d-)" rating on shares of Phreesia in a research report on Wednesday, October 8th. Citigroup restated an "outperform" rating on shares of Phreesia in a research report on Monday, September 8th. Mizuho started coverage on Phreesia in a research report on Wednesday, August 27th. They issued an "outperform" rating and a $36.00 price target for the company. JMP Securities upped their price target on Phreesia from $30.00 to $34.00 and gave the company a "market outperform" rating in a research report on Monday, September 8th. Finally, KeyCorp dropped their price target on Phreesia from $35.00 to $32.00 and set an "overweight" rating for the company in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $33.85.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.